10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

SPL (Starpharma) Stock Analysis
Buy, Hold or Sell?

Let's analyze Starpharma together

I guess you are interested in Starpharma Holdings Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Starpharma’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Starpharma’s Price Targets

I'm going to help you getting a better view of Starpharma Holdings Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Starpharma Holdings Ltd

I send you an email if I find something interesting about Starpharma Holdings Ltd.

1. Quick Overview

1.1. Quick analysis of Starpharma (30 sec.)










1.2. What can you expect buying and holding a share of Starpharma? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
A$0.05
Expected worth in 1 year
A$-0.04
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
A$-0.09
Return On Investment
-69.8%

For what price can you sell your share?

Current Price per Share
A$0.13
Expected price per share
A$0.11 - A$0.135
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Starpharma (5 min.)




Live pricePrice per Share (EOD)
A$0.13
Intrinsic Value Per Share
A$-0.15 - A$0.07
Total Value Per Share
A$-0.11 - A$0.11

2.2. Growth of Starpharma (5 min.)




Is Starpharma growing?

Current yearPrevious yearGrowGrow %
How rich?$12.6m$18.7m-$6m-48.0%

How much money is Starpharma making?

Current yearPrevious yearGrowGrow %
Making money-$6.6m-$5.4m-$1.2m-18.3%
Net Profit Margin-203.4%-98.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Starpharma (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#532 / 853

Most Revenue
#375 / 853

Most Profit
#456 / 853

Most Efficient
#505 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Starpharma?

Welcome investor! Starpharma's management wants to use your money to grow the business. In return you get a share of Starpharma.

First you should know what it really means to hold a share of Starpharma. And how you can make/lose money.

Speculation

The Price per Share of Starpharma is A$0.125. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Starpharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Starpharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.05. Based on the TTM, the Book Value Change Per Share is A$-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Starpharma.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.02-12.7%-0.02-12.7%-0.01-10.4%-0.02-14.3%-0.02-17.7%-0.02-15.7%
Usd Book Value Change Per Share-0.01-11.6%-0.01-11.6%-0.01-8.5%-0.02-12.5%0.00-3.1%0.00-2.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.0111.8%0.019.9%
Usd Total Gains Per Share-0.01-11.6%-0.01-11.6%-0.01-8.5%-0.02-12.5%0.018.7%0.017.5%
Usd Price Per Share0.06-0.06-0.06-0.11-0.36-0.52-
Price to Earnings Ratio-3.68--3.68--4.87--5.61--13.54--16.17-
Price-to-Total Gains Ratio-4.04--4.04--5.93--6.51--6.74--15.90-
Price to Book Ratio1.94-1.94-1.41-2.36-4.70-7.16-
Price-to-Total Gains Ratio-4.04--4.04--5.93--6.51--6.74--15.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0832
Number of shares12019
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.01
Gains per Quarter (12019 shares)-174.41129.98
Gains per Year (12019 shares)-697.64519.90
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-698-708709-189510
20-1395-14061417-3771030
30-2093-21042126-5661550
40-2791-28022834-7552070
50-3488-35003543-9432590
60-4186-41984251-11323110
70-4883-48964960-13213630
80-5581-55945668-15094150
90-6279-62926377-16984670
100-6976-69907086-18865190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%2.024.00.07.7%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%3.07.00.030.0%11.015.00.042.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%1.00.04.020.0%2.00.08.020.0%3.00.023.011.5%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%3.07.00.030.0%11.015.00.042.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Starpharma Holdings Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.022-0.0220%-0.016-27%-0.023+7%-0.006-73%-0.004-80%
Book Value Per Share--0.0450.0450%0.067-32%0.065-30%0.092-51%0.103-56%
Current Ratio--4.3174.3170%4.941-13%4.171+3%5.045-14%6.642-35%
Debt To Asset Ratio--0.2530.2530%0.236+7%0.274-8%0.248+2%0.191+33%
Debt To Equity Ratio--0.3380.3380%0.309+9%0.381-11%0.337+0%0.247+37%
Dividend Per Share----0%-0%-0%0.022-100%0.019-100%
Enterprise Value--30380799.29630380799.2960%54393374.240-44%77444307.019-61%249752755.635-88%354545636.298-91%
Eps---0.024-0.0240%-0.020-18%-0.027+13%-0.033+39%-0.029+23%
Ev To Sales Ratio--6.1856.1850%6.562-6%20.985-71%102.246-94%108.828-94%
Free Cash Flow Per Share---0.016-0.0160%-0.017+4%-0.022+37%-0.027+68%-0.030+83%
Free Cash Flow To Equity Per Share---0.019-0.0190%-0.028+49%-0.028+45%-0.007-64%-0.012-37%
Gross Profit Margin--1.0001.0000%1.449-31%1.219-18%1.205-17%1.176-15%
Intrinsic Value_10Y_max--0.067----------
Intrinsic Value_10Y_min---0.153----------
Intrinsic Value_1Y_max---0.016----------
Intrinsic Value_1Y_min---0.026----------
Intrinsic Value_3Y_max---0.031----------
Intrinsic Value_3Y_min---0.070----------
Intrinsic Value_5Y_max---0.025----------
Intrinsic Value_5Y_min---0.104----------
Market Cap52278124.000+30%36803799.29636803799.2960%39731374.240-7%68728307.019-46%228183555.635-84%324249836.298-89%
Net Profit Margin---2.034-2.0340%-0.985-52%-2.780+37%-4.553+124%-4.134+103%
Operating Margin----0%-1.2970%-2.2970%-4.5860%-4.2060%
Operating Ratio--0.2490.2490%2.829-91%4.158-94%7.104-96%6.022-96%
Pb Ratio2.752+30%1.9371.9370%1.413+37%2.358-18%4.701-59%7.155-73%
Pe Ratio-5.233-42%-3.684-3.6840%-4.866+32%-5.614+52%-13.537+267%-16.168+339%
Price Per Share0.125+30%0.0880.0880%0.095-7%0.164-46%0.546-84%0.775-89%
Price To Free Cash Flow Ratio-7.687-42%-5.412-5.4120%-5.623+4%-6.731+24%-16.767+210%-25.893+378%
Price To Total Gains Ratio-5.734-42%-4.036-4.0360%-5.931+47%-6.505+61%-6.736+67%-15.901+294%
Quick Ratio--0.7720.7720%4.458-83%2.743-72%4.097-81%6.052-87%
Return On Assets---0.393-0.3930%-0.222-44%-0.305-22%-0.286-27%-0.286-27%
Return On Equity---0.526-0.5260%-0.290-45%-0.422-20%-0.383-27%-0.359-32%
Total Gains Per Share---0.022-0.0220%-0.016-27%-0.023+7%0.016-234%0.014-255%
Usd Book Value--12645068.80012645068.8000%18714009.600-32%18177314.133-30%25641840.640-51%28622663.680-56%
Usd Book Value Change Per Share---0.015-0.0150%-0.011-27%-0.016+7%-0.004-73%-0.003-80%
Usd Book Value Per Share--0.0300.0300%0.045-32%0.043-30%0.061-51%0.068-56%
Usd Dividend Per Share----0%-0%-0%0.015-100%0.012-100%
Usd Enterprise Value--20221460.01120221460.0110%36204229.894-44%51546930.752-61%166235434.151-88%235985575.520-91%
Usd Eps---0.016-0.0160%-0.013-18%-0.018+13%-0.022+39%-0.020+23%
Usd Free Cash Flow---4526745.600-4526745.6000%-4703129.600+4%-6216925.867+37%-7597690.880+68%-8298767.360+83%
Usd Free Cash Flow Per Share---0.011-0.0110%-0.011+4%-0.015+37%-0.018+68%-0.020+83%
Usd Free Cash Flow To Equity Per Share---0.013-0.0130%-0.019+49%-0.018+45%-0.004-64%-0.008-37%
Usd Market Cap34796319.334+30%24496608.81124496608.8110%26445202.694-7%45745561.152-46%151878974.631-84%215820691.040-89%
Usd Price Per Share0.083+30%0.0590.0590%0.063-7%0.109-46%0.363-84%0.516-89%
Usd Profit---6649344.000-6649344.0000%-5434624.000-18%-7497540.267+13%-9275668.480+39%-9678156.800+46%
Usd Revenue--3269427.2003269427.2000%5517158.400-41%3580928.000-9%3011174.400+9%2965314.560+10%
Usd Total Gains Per Share---0.015-0.0150%-0.011-27%-0.016+7%0.011-234%0.009-255%
 EOD+5 -3MRQTTM+0 -0YOY+8 -283Y+20 -165Y+12 -2610Y+12 -26

3.3 Fundamental Score

Let's check the fundamental score of Starpharma Holdings Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.233
Price to Book Ratio (EOD)Between0-12.752
Net Profit Margin (MRQ)Greater than0-2.034
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.772
Current Ratio (MRQ)Greater than14.317
Debt to Asset Ratio (MRQ)Less than10.253
Debt to Equity Ratio (MRQ)Less than10.338
Return on Equity (MRQ)Greater than0.15-0.526
Return on Assets (MRQ)Greater than0.05-0.393
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Starpharma Holdings Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.497
Ma 20Greater thanMa 500.126
Ma 50Greater thanMa 1000.115
Ma 100Greater thanMa 2000.103
OpenGreater thanClose0.125
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of a dendrimer-enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial. In addition, the company is developing DEP HER2 radiodiagnostic and DEP HER2 ADC to treat solid tumors; SPL7013 for vaginal gel, is a treatment of bacterial vaginosis and prevention of recurrent BV, and an antiviral condom; and DEP HER2 radiodiagnostic. It has a collaboration agreement with Medicxi to develop petalion therapeutics, a novel cancer therapy using Starpharma's dendrimer technology. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Fundamental data was last updated by Penke on 2025-09-17 10:03:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Starpharma earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Starpharma to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -203.4%Β means thatΒ $-2.03 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Starpharma Holdings Ltd:

  • The MRQ is -203.4%. The company is making a huge loss. -2
  • The TTM is -203.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-203.4%TTM-203.4%0.0%
TTM-203.4%YOY-98.5%-104.9%
TTM-203.4%5Y-455.3%+251.9%
5Y-455.3%10Y-413.4%-41.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-203.4%-85.5%-117.9%
TTM-203.4%-171.0%-32.4%
YOY-98.5%-210.0%+111.5%
3Y-278.0%-289.9%+11.9%
5Y-455.3%-381.1%-74.2%
10Y-413.4%-520.3%+106.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Starpharma is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Starpharma to theΒ Biotechnology industry mean.
  • -39.3% Return on Assets means thatΒ Starpharma generatedΒ $-0.39 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Starpharma Holdings Ltd:

  • The MRQ is -39.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -39.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-39.3%TTM-39.3%0.0%
TTM-39.3%YOY-22.2%-17.1%
TTM-39.3%5Y-28.6%-10.7%
5Y-28.6%10Y-28.6%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-39.3%-11.9%-27.4%
TTM-39.3%-11.9%-27.4%
YOY-22.2%-11.2%-11.0%
3Y-30.5%-12.0%-18.5%
5Y-28.6%-11.7%-16.9%
10Y-28.6%-13.8%-14.8%
4.3.1.3. Return on Equity

Shows how efficient Starpharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Starpharma to theΒ Biotechnology industry mean.
  • -52.6% Return on Equity means Starpharma generated $-0.53Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Starpharma Holdings Ltd:

  • The MRQ is -52.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -52.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-52.6%TTM-52.6%0.0%
TTM-52.6%YOY-29.0%-23.5%
TTM-52.6%5Y-38.3%-14.3%
5Y-38.3%10Y-35.9%-2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-52.6%-14.2%-38.4%
TTM-52.6%-15.2%-37.4%
YOY-29.0%-15.3%-13.7%
3Y-42.2%-16.9%-25.3%
5Y-38.3%-17.5%-20.8%
10Y-35.9%-19.6%-16.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Starpharma Holdings Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Starpharma is operatingΒ .

  • Measures how much profit Starpharma makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Starpharma to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Starpharma Holdings Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-129.7%+129.7%
TTM-5Y-458.6%+458.6%
5Y-458.6%10Y-420.6%-37.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--154.1%+154.1%
TTM--280.2%+280.2%
YOY-129.7%-268.7%+139.0%
3Y-229.7%-281.5%+51.8%
5Y-458.6%-350.8%-107.8%
10Y-420.6%-530.7%+110.1%
4.3.2.2. Operating Ratio

Measures how efficient Starpharma is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.25 means that the operating costs are $0.25 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.249. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.249. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.249TTM0.2490.000
TTM0.249YOY2.829-2.580
TTM0.2495Y7.104-6.855
5Y7.10410Y6.022+1.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2491.952-1.703
TTM0.2492.974-2.725
YOY2.8293.047-0.218
3Y4.1583.835+0.323
5Y7.1044.924+2.180
10Y6.0226.864-0.842
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Starpharma Holdings Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Starpharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 4.32Β means the company has $4.32 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 4.317. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.317. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.317TTM4.3170.000
TTM4.317YOY4.941-0.624
TTM4.3175Y5.045-0.729
5Y5.04510Y6.642-1.596
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3173.480+0.837
TTM4.3173.790+0.527
YOY4.9414.104+0.837
3Y4.1714.609-0.438
5Y5.0455.764-0.719
10Y6.6426.154+0.488
4.4.3.2. Quick Ratio

Measures if Starpharma is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Starpharma to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.77Β means the company can pay off $0.77 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.772. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.772. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.772TTM0.7720.000
TTM0.772YOY4.458-3.686
TTM0.7725Y4.097-3.325
5Y4.09710Y6.052-1.955
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7722.938-2.166
TTM0.7723.291-2.519
YOY4.4583.928+0.530
3Y2.7434.393-1.650
5Y4.0975.837-1.740
10Y6.0526.549-0.497
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Starpharma Holdings Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of StarpharmaΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Starpharma to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.25Β means that Starpharma assets areΒ financed with 25.3% credit (debt) and the remaining percentage (100% - 25.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.253. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.253. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.253TTM0.2530.000
TTM0.253YOY0.236+0.016
TTM0.2535Y0.248+0.005
5Y0.24810Y0.191+0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2530.339-0.086
TTM0.2530.359-0.106
YOY0.2360.334-0.098
3Y0.2740.341-0.067
5Y0.2480.349-0.101
10Y0.1910.379-0.188
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Starpharma is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Starpharma to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 33.8% means that company has $0.34 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Starpharma Holdings Ltd:

  • The MRQ is 0.338. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.338. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.338TTM0.3380.000
TTM0.338YOY0.309+0.029
TTM0.3385Y0.337+0.001
5Y0.33710Y0.247+0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3380.391-0.053
TTM0.3380.436-0.098
YOY0.3090.436-0.127
3Y0.3810.461-0.080
5Y0.3370.461-0.124
10Y0.2470.514-0.267
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Starpharma generates.

  • Above 15 is considered overpriced butΒ always compareΒ Starpharma to theΒ Biotechnology industry mean.
  • A PE ratio of -3.68 means the investor is paying $-3.68Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -5.233. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.684. Based on the earnings, the company is expensive. -2
  • The TTM is -3.684. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.233MRQ-3.684-1.549
MRQ-3.684TTM-3.6840.000
TTM-3.684YOY-4.866+1.182
TTM-3.6845Y-13.537+9.853
5Y-13.53710Y-16.168+2.631
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.233-2.539-2.694
MRQ-3.684-2.361-1.323
TTM-3.684-2.657-1.027
YOY-4.866-3.749-1.117
3Y-5.614-3.883-1.731
5Y-13.537-6.353-7.184
10Y-16.168-7.102-9.066
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Starpharma Holdings Ltd:

  • The EOD is -7.687. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.412. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.412. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.687MRQ-5.412-2.275
MRQ-5.412TTM-5.4120.000
TTM-5.412YOY-5.623+0.211
TTM-5.4125Y-16.767+11.356
5Y-16.76710Y-25.893+9.126
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.687-3.411-4.276
MRQ-5.412-2.951-2.461
TTM-5.412-3.614-1.798
YOY-5.623-4.421-1.202
3Y-6.731-5.258-1.473
5Y-16.767-8.587-8.180
10Y-25.893-9.639-16.254
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Starpharma is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.94 means the investor is paying $1.94Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Starpharma Holdings Ltd:

  • The EOD is 2.752. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.937. Based on the equity, the company is underpriced. +1
  • The TTM is 1.937. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.752MRQ1.937+0.815
MRQ1.937TTM1.9370.000
TTM1.937YOY1.413+0.524
TTM1.9375Y4.701-2.764
5Y4.70110Y7.155-2.454
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7522.206+0.546
MRQ1.9372.027-0.090
TTM1.9372.194-0.257
YOY1.4132.425-1.012
3Y2.3582.571-0.213
5Y4.7013.805+0.896
10Y7.1554.462+2.693
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Starpharma Holdings Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets25,421
Total Liabilities6,423
Total Stockholder Equity18,998
 As reported
Total Liabilities 6,423
Total Stockholder Equity+ 18,998
Total Assets = 25,421

Assets

Total Assets25,421
Total Current Assets22,560
Long-term Assets2,861
Total Current Assets
Cash And Cash Equivalents 15,407
Net Receivables 4,037
Inventory 1,915
Total Current Assets  (as reported)22,560
Total Current Assets  (calculated)21,359
+/- 1,201
Long-term Assets
Property Plant Equipment 2,861
Long-term Assets  (as reported)2,861
Long-term Assets  (calculated)2,861
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,226
Long-term Liabilities1,197
Total Stockholder Equity18,998
Total Current Liabilities
Short Long Term Debt 444
Accounts payable 2,054
Total Current Liabilities  (as reported)5,226
Total Current Liabilities  (calculated)2,498
+/- 2,728
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,958
Long-term Liabilities  (as reported)1,197
Long-term Liabilities  (calculated)1,958
+/- 761
Total Stockholder Equity
Total Stockholder Equity (as reported)18,998
Total Stockholder Equity (calculated)0
+/- 18,998
Other
Capital Stock240,750
Common Stock Shares Outstanding 418,225
Net Invested Capital 19,442
Net Working Capital 17,334
Property Plant and Equipment Gross 6,493



5.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-30
> Total Assets 
0
0
29,053
26,025
18,859
10,715
18,491
12,500
25,013
30,423
24,653
28,847
37,567
29,807
54,268
48,550
36,862
44,383
59,039
66,591
58,511
48,859
39,078
73,238
66,175
52,086
36,814
25,421
25,42136,81452,08666,17573,23839,07848,85958,51166,59159,03944,38336,86248,55054,26829,80737,56728,84724,65330,42325,01312,50018,49110,71518,85926,02529,05300
   > Total Current Assets 
0
0
28,936
25,789
17,838
8,459
16,242
8,354
17,108
11,408
9,255
13,176
24,230
19,941
44,865
39,332
28,598
35,080
50,276
65,678
57,453
47,809
36,676
70,755
60,658
47,122
32,919
22,560
22,56032,91947,12260,65870,75536,67647,80957,45365,67850,27635,08028,59839,33244,86519,94124,23013,1769,25511,40817,1088,35416,2428,45917,83825,78928,93600
       Cash And Cash Equivalents 
0
0
28,079
25,412
17,434
7,892
15,658
8,166
14,284
10,073
7,482
11,595
22,851
18,918
42,812
33,840
24,028
30,848
45,972
61,188
51,319
41,251
30,054
60,500
49,918
35,180
23,360
15,407
15,40723,36035,18049,91860,50030,05441,25151,31961,18845,97230,84824,02833,84042,81218,91822,85111,5957,48210,07314,2848,16615,6587,89217,43425,41228,07900
       Net Receivables 
0
0
698
305
150
420
421
43
2,664
899
1,403
1,481
1,323
870
1,917
5,314
4,211
3,866
3,938
3,838
5,911
959
6,087
8,439
7,836
8,235
6,340
4,037
4,0376,3408,2357,8368,4396,0879595,9113,8383,9383,8664,2115,3141,9178701,3231,4811,4038992,6644342142015030569800
       Other Current Assets 
0
0
158
72
253
148
113
145
160
436
370
100
56
153
136
178
359
366
366
652
223
5,200
41
95
80
934
811
0
08119348095415,200223652366366359178136153561003704361601451131482537215800
   > Long-term Assets 
0
0
117
236
1,022
2,256
2,248
4,146
7,905
19,016
15,398
15,671
13,337
9,866
9,403
9,218
8,264
9,303
8,763
913
1,058
1,050
2,402
2,483
5,517
4,964
3,895
2,861
2,8613,8954,9645,5172,4832,4021,0501,0589138,7639,3038,2649,2189,4039,86613,33715,67115,39819,0167,9054,1462,2482,2561,02223611700
       Property Plant Equipment 
0
0
117
236
948
2,005
1,556
1,233
1,431
1,111
758
447
219
280
414
411
509
910
690
913
1,058
1,050
2,402
2,483
5,517
4,964
3,895
2,861
2,8613,8954,9645,5172,4832,4021,0501,0589136909105094114142802194477581,1111,4311,2331,5562,00594823611700
       Goodwill 
0
0
0
0
0
0
0
0
0
1,755
1,547
1,835
1,747
1,387
1,461
1,606
1,581
1,939
2,005
0
0
0
0
0
0
0
0
0
0000000002,0051,9391,5811,6061,4611,3871,7471,8351,5471,755000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
4,087
16,031
13,093
13,389
11,371
8,199
7,528
7,201
6,174
6,454
6,068
0
0
0
0
0
0
0
0
0
0000000006,0686,4546,1747,2017,5288,19911,37113,38913,09316,0314,08700000000
       Other Assets 
0
0
0
0
74
0
0
0
0
43
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000430000740000
> Total Liabilities 
0
0
199
1,110
1,593
1,472
898
2,534
3,697
4,699
4,270
3,348
2,723
2,114
5,617
2,582
3,911
6,825
9,615
5,607
5,234
6,464
7,752
10,938
17,782
17,271
8,698
6,423
6,4238,69817,27117,78210,9387,7526,4645,2345,6079,6156,8253,9112,5825,6172,1142,7233,3484,2704,6993,6972,5348981,4721,5931,11019900
   > Total Current Liabilities 
0
0
199
1,110
1,593
1,269
755
2,365
3,033
3,260
3,715
3,143
2,665
2,041
5,435
2,459
3,844
6,769
9,575
5,521
5,164
6,426
6,697
10,429
10,231
14,473
6,662
5,226
5,2266,66214,47310,23110,4296,6976,4265,1645,5219,5756,7693,8442,4595,4352,0412,6653,1433,7153,2603,0332,3657551,2691,5931,11019900
       Short-term Debt 
0
0
0
0
43
60
60
60
142
69
124
133
160
49
40
25
27
30
18
23
26
26
604
692
695
5,522
1,571
0
01,5715,52269569260426262318302725404916013312469142606060430000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75
48
18
70
49
0
0
0
0
4,778
775
444
4447754,778000049701848750000000000000000
       Accounts payable 
0
0
160
1,016
1,208
670
429
1,647
1,898
1,855
1,623
1,764
1,346
940
4,156
1,208
2,586
5,481
8,210
4,034
3,023
4,098
4,394
6,711
6,762
6,615
2,725
2,054
2,0542,7256,6156,7626,7114,3944,0983,0234,0348,2105,4812,5861,2084,1569401,3461,7641,6231,8551,8981,6474296701,2081,01616000
       Other Current Liabilities 
0
0
39
93
214
257
266
280
331
-624
417
316
530
703
842
1,115
1,187
1,184
1,347
1,453
1,708
1,875
1,262
2,614
2,308
2,333
2,338
0
02,3382,3332,3082,6141,2621,8751,7081,4531,3471,1841,1871,115842703530316417-624331280266257214933900
   > Long-term Liabilities 
0
0
0
0
0
204
144
169
664
1,440
555
205
58
73
182
123
67
56
40
86
70
38
1,055
509
7,551
2,798
2,036
1,197
1,1972,0362,7987,5515091,05538708640566712318273582055551,44066416914420400000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
0
47
23
0
970
475
7,494
2,750
1,957
0
01,9572,7507,4944759700234701800000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
89
349
226
134
45
58
56
82
48
19
38
40
39
47
38
85
34
57
48
0
0
00485734853847394038194882565845134226349890000000
> Total Stockholder Equity
0
0
28,853
24,916
17,010
9,243
17,592
9,966
21,316
25,724
20,383
25,499
34,844
27,693
48,651
45,968
32,951
37,558
49,424
60,984
53,277
42,395
31,326
62,300
48,393
34,815
28,116
18,998
18,99828,11634,81548,39362,30031,32642,39553,27760,98449,42437,55832,95145,96848,65127,69334,84425,49920,38325,72421,3169,96617,5929,24317,01024,91628,85300
   Common Stock
0
0
33,065
33,034
33,034
33,034
46,822
46,822
65,375
76,227
78,667
85,640
101,766
105,399
139,171
140,081
140,349
160,884
193,512
193,549
193,583
193,621
193,661
240,630
240,669
240,715
240,750
0
0240,750240,715240,669240,630193,661193,621193,583193,549193,512160,884140,349140,081139,171105,399101,76685,64078,66776,22765,37546,82246,82233,03433,03433,03433,06500
   Retained Earnings Total Equity0000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-23
-86
-259
-47
13
-28
497
1,299
1,009
3,279
2,876
1,022
1,866
3,502
4,852
7,874
9,787
10,896
13,440
16,775
20,340
24,077
26,285
28,299
29,730
0
029,73028,29926,28524,07720,34016,77513,44010,8969,7877,8744,8523,5021,8661,0222,8763,2791,0091,299497-2813-47-259-86-2300
   Capital Surplus 0000000000000000000000000000
   Treasury Stock0000000000000000000000000000
   Other Stockholders Equity 
0
0
23
86
259
0
0
0
0
0
0
0
0
0
0
0
4,852
0
0
10,896
13,440
0
-10,986
-38,223
-22,108
-6,516
0
0
00-6,516-22,108-38,223-10,986013,44010,896004,85200000000000259862300



5.3. Balance Sheets

Currency in AUD. All numbers in thousands.




5.4. Cash Flows

Currency in AUD. All numbers in thousands.




5.5. Income Statements

Currency in AUD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2025-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,912
Cost of Revenue-1,224
Gross Profit3,6883,688
 
Operating Income (+$)
Gross Profit3,688
Operating Expense-0
Operating Income-11,9983,688
 
Operating Expense (+$)
Research Development8,355
Selling General Administrative3,031
Selling And Marketing Expenses0
Operating Expense011,386
 
Net Interest Income (+$)
Interest Income938
Interest Expense-0
Other Finance Cost-0
Net Interest Income938
 
Pretax Income (+$)
Operating Income-11,998
Net Interest Income938
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-9,990-11,998
EBIT - interestExpense = 0
-9,990
-9,990
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-9,990
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-9,990
Tax Provision-0
Net Income From Continuing Ops-9,990-9,990
Net Income-9,990
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-938
 

Technical Analysis of Starpharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Starpharma. The general trend of Starpharma is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Starpharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Starpharma Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Starpharma Holdings Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.135 < 0.135 < 0.135.

The bearish price targets are: 0.11 > 0.11 > 0.11.

Know someone who trades $SPL? Share this with them.πŸ‘‡

Starpharma Holdings Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Starpharma Holdings Ltd. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Starpharma Holdings Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Starpharma Holdings Ltd. The current macd is 0.00225851.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Starpharma price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Starpharma. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Starpharma price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Starpharma Holdings Ltd Daily Moving Average Convergence/Divergence (MACD) ChartStarpharma Holdings Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Starpharma Holdings Ltd. The current adx is 24.82.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Starpharma shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Starpharma Holdings Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Starpharma Holdings Ltd. The current sar is 0.12724674.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Starpharma Holdings Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Starpharma Holdings Ltd. The current rsi is 52.50. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Starpharma Holdings Ltd Daily Relative Strength Index (RSI) ChartStarpharma Holdings Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Starpharma Holdings Ltd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Starpharma price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Starpharma Holdings Ltd Daily Stochastic Oscillator ChartStarpharma Holdings Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Starpharma Holdings Ltd. The current cci is -11.43200963.

Starpharma Holdings Ltd Daily Commodity Channel Index (CCI) ChartStarpharma Holdings Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Starpharma Holdings Ltd. The current cmo is 2.26952825.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Starpharma Holdings Ltd Daily Chande Momentum Oscillator (CMO) ChartStarpharma Holdings Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Starpharma Holdings Ltd. The current willr is -40.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Starpharma is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Starpharma Holdings Ltd Daily Williams %R ChartStarpharma Holdings Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Starpharma Holdings Ltd.

Starpharma Holdings Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Starpharma Holdings Ltd. The current atr is 0.00685516.

Starpharma Holdings Ltd Daily Average True Range (ATR) ChartStarpharma Holdings Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Starpharma Holdings Ltd. The current obv is -20,045,397.

Starpharma Holdings Ltd Daily On-Balance Volume (OBV) ChartStarpharma Holdings Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Starpharma Holdings Ltd. The current mfi is 45.99.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Starpharma Holdings Ltd Daily Money Flow Index (MFI) ChartStarpharma Holdings Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Starpharma Holdings Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-06-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-07-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-30MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-17STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Starpharma Holdings Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Starpharma Holdings Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.497
Ma 20Greater thanMa 500.126
Ma 50Greater thanMa 1000.115
Ma 100Greater thanMa 2000.103
OpenGreater thanClose0.125
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Starpharma with someone you think should read this too:
  • Are you bullish or bearish on Starpharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Starpharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Starpharma Holdings Ltd

I send you an email if I find something interesting about Starpharma Holdings Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Starpharma Holdings Ltd.

Receive notifications about Starpharma Holdings Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.